Home Cart Sign in  
Chemical Structure| 1309357-15-0 Chemical Structure| 1309357-15-0

Structure of Silmitasertib sodium salt
CAS No.: 1309357-15-0

Chemical Structure| 1309357-15-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Silmitasertib sodium salt is an orally bioavailable, highly selective, and potent CK2 inhibitor with IC50 values of 1 nM against CK2α and CK2α'.

Synonyms: CX-4945 sodium salt; CX-4945 Sodium

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Silmitasertib sodium salt

CAS No. :1309357-15-0
Formula : C19H11ClN3NaO2
M.W : 371.75
SMILES Code : O=C(C1=CC=C2C3=C(C(NC4=CC=CC(Cl)=C4)=NC2=C1)C=CN=C3)[O-].[Na+]
Synonyms :
CX-4945 sodium salt; CX-4945 Sodium
MDL No. :MFCD28385881
InChI Key :ODDAAPQSODILSN-UHFFFAOYSA-M
Pubchem ID :49788959

Safety of Silmitasertib sodium salt

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Silmitasertib sodium salt

DNA
Hedgehog

Isoform Comparison

Biological Activity

Target
  • CK2

    CK2α', IC50:1 nM

    CK2α, IC50:1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
U87MG cells 25 μM 6 h To evaluate the effect of Silmitasertib on the stability of ECE1c protein, results showed that ECE1cK6R remained highly stable in the presence of Silmitasertib. PMC9914402
Cal-27 10, 20, 40 µM 24, 48 h Silmitasertib combined with DDP significantly reduced cell viability, showing a synergistic effect. PMC8592591
UM1 10, 20, 40 µM 24, 48 h Silmitasertib combined with DDP significantly reduced cell viability, showing a synergistic effect. PMC8592591
HSC-3 10, 20, 40 µM 12 h Silmitasertib induced the formation of vacuoles of different numbers and sizes in HSC-3 cells. PMC8592591
HSC-4 10, 20, 40 µM 12 h Silmitasertib induced the formation of vacuoles of different numbers and sizes in HSC-4 cells. PMC8592591
OSC19 10 µM 12 h Silmitasertib significantly inhibited invadopodia function and ECM degradation in OSC19 cells PMC6445698
UMSCC1 10 µM 12 h Silmitasertib significantly inhibited invadopodia function and ECM degradation in UMSCC1 cells PMC6445698
MDA1586 10 µM 24 h Silmitasertib significantly inhibited invadopodia function and ECM degradation in MDA1586 cells PMC6445698

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice subcutaneous xenograft model of ovarian cancer oral 60 mg/kg twice daily, until the end of the experiment Silmitasertib significantly inhibited tumor growth PMC11743126
BALB/c nude mice Cal-27 xenograft model Peritumoral injection 60 mg/kg Once every 5 days for 4 weeks Silmitasertib combined with DDP significantly suppressed tumor growth and showed a synergistic effect. PMC8592591
mice NSG mice oral 50 mg/kg twice daily for three weeks Silmitasertib significantly inhibited tumor invasion in mice PMC6445698

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.45mL

2.69mL

1.34mL

26.90mL

5.38mL

2.69mL

References

 

Historical Records

Categories